MAPT and Alzheimer disease: In soluble tau (Table 2, bottom panel), Ub-K369 ranked among 4R-specific PTMs since observed in all CBD cases (100%), in 50% of the FTLD-4R subjects, and in a minority (20%) of AD cases while completely absent in individuals with PiD or FTLD-3R.